课题基金 / 基金详情

Kaiser Washington Vaccine and Treatment Evaluation Unit – DMID 21-0004

Kaiser Washington Vaccine and Treatment Evaluation Unit – DMID 21-0004
凯撒华盛顿疫苗和治疗评估单位 — DMID 21-0004
批准号：
10523479
负责人：
LISA A JACKSON
金额：
$211.45万
依托单位：
KAISER FOUNDATION RESEARCH INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
项目状态：
已结题
起止时间：
2022-04-07 至 2023-11-30
来源：
https://reporter.nih.gov/project-details/10523479
关键词：
2019-nCoVBiological AssayCOVID-19 vaccineChildEvaluationFundingPostpartum PeriodPregnancyProtocols documentationResearch InstituteSafetyUnited States National Institutes of HealthVaccinesWashingtonWorkclinical research siteimmunogenicity

项目摘要

项目成果

LISA A JACKSON的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The 21-0004 protocol will evaluate the safety and immunogenicity of SARS-CoV-2 administered during pregnancy or postpartum. The Seattle Children’s Research Institute, a subcontractor to the Kaiser Washington VTEU, has been selected to perform SARS-CoV-2 pseudovirus neutralization assays for the 21-0004 trial. The NIH will provide funds for the assay work to the Kaiser Washington VTEU, which will then provide funds to the Seattle Children’s Research Institute via the existing subcontract. Kaiser Washington is not a clinical site for the 21-0004 trial and the work of the subcontractor is the only involvement of Kaiser Washington in that trial.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Kaiser Washington Vaccine and Treatment Evaluation Unit
Kaiser Washington Vaccine and Treatment Evaluation Unit - DMID 21-0012
Kaiser Washington Vaccine and Treatment Evaluation Unit
Kaiser Washington Vaccine and Treatment Evaluation Unit
海外基金